• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Rev Med Virol . Severe acute respiratory syndrome-coronavirus-2: Current advances in therapeutic targets and drug development

tetano

Editor, Senior Moderator
Rev Med Virol


. 2020 Sep 23.
doi: 10.1002/rmv.2174. Online ahead of print.
Severe acute respiratory syndrome-coronavirus-2: Current advances in therapeutic targets and drug development


Sakthivel Suganya[SUP] 1 2 [/SUP], Suresh Divya[SUP] 3 4 [/SUP], Madasamy Parani[SUP] 4 [/SUP]



Affiliations

Abstract

The current pandemic of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) has quickly emerged as a global health concern with government bodies worldwide taking drastic control measures. Understanding the virology of SARS-CoV-2, its molecular mechanisms, and its pathogenesis are required for a targeted therapeutic approach. In this review, we highlight the current molecular and drug advances that target SARS-CoV-2 at the genome level. We also summarize studies that therapeutically target the host angiotensin-converting enzyme 2 and proteases. Finally, we summarize antibody-mediated therapeutic approaches, as well as recent trends in vaccine development. Hence, the purpose of this study is to investigate different molecular targets in SARS-CoV-2 pathogenesis and their usefulness in developing strategies for drug development.

Keywords: ACE2; SARS-CoV-2; TMPRSS2; antibodies; vaccine development; virus.
 
Back
Top Bottom